TELA Bio Posts 18% Q4 Revenue Rise to $20.9M, Secures $70M Credit Facility
TELA Bio reported Q4 revenue of $20.9M and full-year revenue of $80.3M, up 18% and 16% year-over-year, and cut Q4 operating loss from $8.4M to $6.6M. It secured a $70M credit facility, expanded its sales force to 88 reps and projects at least 8% growth in 2026.
1. Q4 2025 Financial Results
In the fourth quarter ended December 31, 2025, revenue rose 18% to $20.9 million, while gross profit increased to $13.8 million or 65.9% of revenue. Operating expenses were $20.4 million, driving an operating loss of $6.6 million versus $8.4 million a year earlier and a net loss of $9.0 million.
2. Full Year 2025 Financial Performance
For the full year, revenue reached $80.3 million, up 16% year-over-year, with gross profit of $54.3 million or 67.7% of revenue. Operating expenses held flat at $88.1 million, producing an operating loss of $33.8 million and a net loss of $38.8 million, while cash and equivalents totaled $50.8 million at year-end.
3. Leadership and Strategic Initiatives
The company promoted Howard Langstein, MD, FACS to Chief Medical Officer, expanded its quota-carrying sales force to 88 representatives and launched the larger-sized OviTex PRS product configuration in the U.S. These moves aim to deepen market penetration and support sustainable sales growth.
4. Credit Facility and Outlook
TELA secured a credit facility of up to $70.0 million, including an initial $60.0 million loan and an additional $10.0 million available by April 30, 2027 upon meeting revenue thresholds. The company forecasts at least 8% full-year revenue growth in 2026 and expects Q1 revenue of approximately $18.5 million.